Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study

Roblot, P.; Moal, G. Le; Godet, C.; Hutin, P.; Texereau, Michèle; Boyer, E; Prazuck, Thiérry; Lacroix, C.; Souala, Mohamed Faouzi; Raffi, François; Weinbreck, P.; Besnier, Jean-Marc; Garo, B.; Gentile, Ludovic de; Becq‐Giraudon, B.

doi:10.1016/s0163-4453(03)00038-0

Cited by 73 publications

(54 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prognosis is generally good if therapy is initiated before respiratory capacity is affected. High CRP predicted a poor prognosis in this as well as in a previous study [3], probably reflecting the vigorous inflammation that seems to contribute to the lung injury and respiratory failure in more advanced disease [4].…”

Section: Letter To the Editorsupporting

confidence: 73%

“…Dear Editor, Lung infections are serious complications in patients with hematological malignancies [1][2][3][4]. Pneumocystis jiroveci is an important causative organism.…”

Section: Letter To the Editormentioning

confidence: 99%

“…However, the precise degree of immunosuppression at which PCP may occur is still not fully elucidated. Thus, we are still not able to identify patients who would benefit from prophylaxis with a satisfactory accuracy [1,3,6].…”

Section: Letter To the Editormentioning

confidence: 99%

“…In hematological patients, more aggressive therapy is continuously evaluated to combat the underlying disease. Cotrimoxazole prophylaxis has been shown to be very effective [4,5], but there is no perfectly apt means to select exactly which patients should be given prophylaxis [1,3]. In HIV patients, a CD4-level below 200 cells/microliter is the accepted criterion, but in nonHIV patients, this limit is not valid enough and there is no other adequate marker of the degree of T cell suppression [6].…”

Section: Letter To the Editormentioning

confidence: 99%

“…In HIV patients, a CD4-level below 200 cells/microliter is the accepted criterion, but in nonHIV patients, this limit is not valid enough and there is no other adequate marker of the degree of T cell suppression [6]. Most patients in previous reports have received steroids [2][3][4], but severe infection in nonsteroid-treated patients have also been reported [1,6]. Thus, clinical data are necessary to identify which patients should be considered for prophylaxis.…”

Section: Letter To the Editormentioning

confidence: 99%

See 4 more Smart Citations

Fatal pneumocystis jiroveci pneumonia in ABVD-treated Hodgkin lymphoma patients

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Letter To the Editorsupporting

confidence: 73%

“…Dear Editor, Lung infections are serious complications in patients with hematological malignancies [1][2][3][4]. Pneumocystis jiroveci is an important causative organism.…”

Section: Letter To the Editormentioning

confidence: 99%

Section: Letter To the Editormentioning

confidence: 99%

Section: Letter To the Editormentioning

confidence: 99%

Section: Letter To the Editormentioning

confidence: 99%

See 3 more Smart Citations

Fatal pneumocystis jiroveci pneumonia in ABVD-treated Hodgkin lymphoma patients

et al. 2009

View full text Add to dashboard Cite

show abstract

Supportive Care: Physical Consequences of Cancer and its Therapies

Phillips

Skinner

2010

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA‐Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide

Nettleton,

Sattui,

Wallace

et al. 2023

Arthritis Care & Research

View full text Add to dashboard Cite

ObjectiveThis manuscript assesses the incidence of Pneumocystis jiroveci pneumonia (PJP) among patients receiving contemporary treatment regimens for antineutrophil cytoplasmic antibody–associated vasculitis (AAV) and adverse events associated with PJP prophylaxis.MethodsIncident users of rituximab or cyclophosphamide for AAV were identified in the TriNetX electronic health records database from 2011 to 2022. The incidence rates (IRs) of PJP in the first 6 months of induction therapy with rituximab and/or cyclophosphamide and during postinduction maintenance therapy with rituximab were calculated. Cox proportional hazard models were used to estimate hazard ratios (HRs) and confidence intervals (CIs) for the risk of adverse events commonly associated with PJP prophylaxis.ResultsWe identified 1,461 AAV cases who received induction therapy with rituximab (69.7%), cyclophosphamide (18.9%), or both (11.4%). Prophylaxis prescribed within 30 days of induction included trimethoprim‐sulfamethoxazole (30.7%), atovaquone (5.4%), dapsone (3.8%), and pentamidine (0.8%). During induction therapy, 10 cases of PJP were identified (IR 15.0 cases per 1,000 patient‐years); no deaths occurred. In adjusted analyses, those who received prophylaxis had a higher risk of leukopenia (HR 3.1; 95% CI 1.1–8.6), rash (HR 1.9; 95% CI 1.0–3.6), and nephropathy (HR 2.6; 95% CI 1.3–5.1) than those who did not. During rituximab maintenance therapy (n = 709), five cases of PJP were identified (IR 2.1 cases per 1,000 person‐years), one of whom died during the hospitalization associated with a PJP diagnosis.ConclusionRates of PJP in patients with AAV were lower than previously observed, and few cases occurred during rituximab maintenance therapy. PJP prophylaxis was associated with adverse events.

show abstract

Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study

Cited by 73 publications

References 39 publications

Fatal pneumocystis jiroveci pneumonia in ABVD-treated Hodgkin lymphoma patients

Fatal pneumocystis jiroveci pneumonia in ABVD-treated Hodgkin lymphoma patients

Supportive Care: Physical Consequences of Cancer and its Therapies

Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA‐Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide

Contact Info

Product

Resources

About